ASST vs OCFC

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm solvency, raising uncertainty. Despite a strong revenue growth of 56.80% YoY and a low Price/Book of 0.74 suggesting possible value, extreme negative operating margins (-3064.29%) and a sky-high Price/Sales ratio of 197.00 signal severe profitability and valuation concerns. The stock has lost over 95% of its value in the past five years, with a current technical trend scoring 0/100, reflecting deep investor skepticism. While the balance sheet shows no debt and high liquidity ratios, these positives are overshadowed by absent profitability, lack of earnings, and minimal analyst coverage.

OCFC presents a classic deep-value profile with a stable Piotroski F-Score of 4/9 and a significant discount to book value (P/B 0.66). While the Graham Number suggests a defensive fair value of $27.75, the growth-based intrinsic value is alarmingly low at $8.26, reflecting a severe -36.20% YoY earnings contraction. The stock exhibits strong 1-year price momentum and a respectable dividend yield, but very low ROE (4.22%) and ROA (0.51%) indicate poor capital efficiency. The valuation is highly attractive, but the fundamental earnings deterioration creates a 'value trap' risk.